According to Ultragenyx Pharmaceutical's latest financial reports the company has S$0.19 Billion in net assets.
A companyโs net assets is the sum of its assets minus the sum of its liabilities.
Year | Net assets | Change |
---|---|---|
2024-12-31 | $S$0.35 B | -1.98% |
2023-12-31 | $S$0.36 B | -23.03% |
2022-12-31 | $S$0.47 B | -62.11% |
2021-12-31 | $S$1.24 B | -18.33% |
2020-12-31 | $S$1.52 B | 73.27% |
2019-12-31 | $S$0.88 B | 5.95% |
2018-12-31 | $S$0.83 B | 62.2% |
2017-12-31 | $S$0.51 B | -25.24% |
2016-12-31 | $S$0.68 B | -8.69% |
2015-12-31 | $S$0.75 B | 207.41% |
2014-12-31 | $S$0.24 B | 284.92% |
2013-12-31 | $S$63.48 M | -38.45% |
2012-12-31 | $S$0.10 B | 648.3% |
2011-12-31 | $S$13.78 M |
Company | Net assets | differencediff. | Country |
---|---|---|---|
![]() BioMarin Pharmaceutical BMRN | S$7.45 B | 3,730.49% | ๐บ๐ธ USA |
![]() Amicus Therapeutics
FOLD | S$0.24 B | 27.98% | ๐บ๐ธ USA |
![]() Esperion Therapeutics ESPR | -S$0.55 Billion | -381.80% | ๐บ๐ธ USA |
![]() Lexicon Pharmaceuticals
LXRX | S$0.15 B | -18.65% | ๐บ๐ธ USA |